TS
ADVM

Thomas Steyer’s Adverum Biotechnologies ADVM Stock Holding History

Thomas Steyer’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$14.8M – 299
2021
Q1 		$14.8M Hold
150,000
– – 0.07% 118
2020
Q4 		$16.3M Hold
150,000
– – 0.1% 96
2020
Q3 		$15.4M Buy
+150,000
New +$22.5M 0.11% 91
2015
Q3 		– Sell
-6,500
Closed -$1.06M – 85
2015
Q2 		$1.06M Hold
6,500
– – 0.01% 93
2015
Q1 		$2.63M Buy
+6,500
New +$2.75M 0.04% 84

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Thomas Steyer's ADVM Position: Q2 2021 in Review

Thomas Steyer sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 150,000 shares — an estimated $14.8M sold.

Thomas Steyer first reported a position in ADVM in Q1 2015 and held it in 5 quarters. The position peaked at $16.3M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Thomas Steyer reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Thomas Steyer sold 150,000 Adverum Biotechnologies shares in Q2 2021, an estimated $14.8M.
  • Thomas Steyer first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 5 quarters.
  • Thomas Steyer's Adverum Biotechnologies position peaked at $16.3M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.